Israel's Scinai Q1 net income turns positive on acquisition gain
Israel's Scinai Q1 net income turns positive on acquisition gain
Overview
Israel biopharma and CDMO firm's Q1 revenue fell yr/yr; net income turned positive on acquisition gain
Company completed Recipharm Israel acquisition in the qtr, expanding CDMO platform and commercial reach
Cost allocation changes impacted cost of revenues and R&D comparability with prior periods
Outlook
Company remains focused on expanding CDMO revenues and integrating its expanded manufacturing platform
Scinai expects several grant funding decisions in the second half of 2026
Company aims to advance PC111 and IL-17 bispecific NanoAb programs and pursue strategic partnerships
Result Drivers
ACQUISITION IMPACT - Net income turned positive due to a non-cash bargain purchase gain from the Recipharm Israel acquisition
CDMO EXPANSION - Increased costs and operating loss driven by expansion of CDMO activities and integration of the Yavne facility
COST ALLOCATION CHANGES - Cost of revenues and R&D expenses not directly comparable due to revised cost allocation methodology
Company press release: ID:nPn5wBQYqa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Net Income |
| $3.6 mln |
|
Q1 Operating Income |
| -$2.50 mln |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)